Stevenson JP - Search Results

1

Mechanisms of hypertension associated with BAY 43-9006.

Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Veronese ML, et al. Among authors: stevenson jp. J Clin Oncol. 2006 Mar 20;24(9):1363-9. doi: 10.1200/JCO.2005.02.0503. Epub 2006 Jan 30. J Clin Oncol. 2006. PMID: 16446323 Clinical Trial.

2

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.

Stevenson JP, Scher RM, Kosierowski R, Fox SC, Simmonds M, Yao KS, Green F, Broom C, Fields SZ, Krebs JB, O'Dwyer PJ. Stevenson JP, et al. Eur J Cancer. 1998 Aug;34(9):1358-62. doi: 10.1016/s0959-8049(98)00053-7. Eur J Cancer. 1998. PMID: 9849417 Clinical Trial.

3

Chemotherapy of advanced colorectal cancer.

O'Dwyer PJ, Stevenson JP. O'Dwyer PJ, et al. Among authors: stevenson jp. Cancer Treat Res. 1998;98:111-52. doi: 10.1007/978-1-4615-4977-2_5. Cancer Treat Res. 1998. PMID: 10326667 Review. No abstract available.

4

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C. Stevenson JP, et al. Ann Oncol. 1999 Mar;10(3):339-44. doi: 10.1023/a:1008313011289. Ann Oncol. 1999. PMID: 10355580 Free article. Clinical Trial.

5

Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule.

Stevenson JP, DeMaria D, Reilly D, Purvis JD, Graham MA, Lockwood G, Drozd M, O'Dwyer PJ. Stevenson JP, et al. Cancer Chemother Pharmacol. 1999;44(3):228-34. doi: 10.1007/s002800050971. Cancer Chemother Pharmacol. 1999. PMID: 10453724 Clinical Trial.

6

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ. Stevenson JP, et al. J Clin Oncol. 1999 Jul;17(7):2227-36. doi: 10.1200/JCO.1999.17.7.2227. J Clin Oncol. 1999. PMID: 10561280 Clinical Trial.

7

c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).

O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS. O'Dwyer PJ, et al. Among authors: stevenson jp. Clin Cancer Res. 1999 Dec;5(12):3977-82. Clin Cancer Res. 1999. PMID: 10632328 Clinical Trial.

8

Clinical pharmacokinetics and administration of established platinum drugs.

O'Dwyer PJ, Stevenson JP, Johnson SW. O'Dwyer PJ, et al. Among authors: stevenson jp. Drugs. 2000;59 Suppl 4:19-27. doi: 10.2165/00003495-200059004-00003. Drugs. 2000. PMID: 10864227 Review.

9

Irinotecan and UFT/leucovorin in patients with advanced cancers.

Stevenson JP, Redlinger M, Sun W, Haller D, O'Dwyer PJ. Stevenson JP, et al. Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):91-2. Oncology (Williston Park). 2000. PMID: 11098504 Free article. Clinical Trial.

10

Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma.

Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM. Robnett TJ, et al. Among authors: stevenson jp. J Clin Oncol. 2001 Mar 1;19(5):1344-9. doi: 10.1200/JCO.2001.19.5.1344. J Clin Oncol. 2001. PMID: 11230477

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters